Brolucizumab-dbll

What is Brolucizumab–dbll?

Brolucizumab–dbll (BEOVU) is a human vascular endothelial growth factor (VEGF) inhibitor.

What are the uses of this medicine?

• This medicine is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

How does this medicine work?

• Brolucizumab is a human VEGF inhibitor.
• Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2.
• By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.

Who Should Not Use this medicine ?

This medicine cannot be used in patients with:

• Ocular or Periocular Infections
• Active Intraocular Inflammation
• known hypersensitivity to brolucizumab or any of the excipients in BEOVU

Is this medicine FDA approved?

• It was approved for use in the United States in 2019.

How should this medicine be used?

Recommended Dosage

• The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25-31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• Intravitreal injection: 6 mg/0.05 mL solution in a single-dose vial.

This medicine is available in fallowing brand namesː

• BEOVU

What side effects can this medication cause?

The most common side effects of this medicine include:

• vision blurred
• cataract
• conjunctival hemorrhage
• eye pain
• vitreous floaters

= What special precautions should I follow?

• Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay.
• Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay.
• Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection, including with BEOVU.
• There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• There are no adequate and well-controlled studies of BEOVU administration in pregnant women.
• BEOVU should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.

Can this medicine be used in children?

• The safety and efficacy of BEOVU in pediatric patients has not been established.

What are the active and inactive ingredients in this medicine?

Active ingredient:

• BROLUCIZUMAB

Inactive ingredients:

• SUCROSE
• SODIUM CITRATE, UNSPECIFIED FORM
• POLYSORBATE 80
• SODIUM HYDROXIDE
• NITROGEN
• WATER

Who manufactures and distributes this medicine?

• Packager: Novartis Pharmaceuticals Corporation

What should I know about storage and disposal of this medication?

• Refrigerate BEOVU between 2°C to 8°C (36°F to 46°F). Do not freeze. Store the vial in the outer carton to protect from light.
• Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20°C to 25°C (68°F to 77°F) for up to 24 hours.

• Dailymed label info on Brolucizumab-dbll
• FDA Brolucizumab-dbll

Brolucizumab-dbll Resources
Latest articles Most recent articles Ongoing trials	Wikipedia